We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Aurinia Pharmaceuticals Inc (AUPH) NPV

Sell:$18.50 Buy:$18.60 Change: $1.14 (5.78%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $1.14 (5.78%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $1.14 (5.78%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Aurinia Pharmaceuticals Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases. The Company has developed LUPKYNISTM, for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory advancement to support the voclosporin development program. LUPKYNIS is a calcineurin inhibitor (CNI) immunosuppressant, that improves near and long-term outcomes in LN when used in combination with mycophenolate mofetil and steroids. LUPKYNIS reduces cytokine activation and blocks interleukin IL-2 expression and T-cell mediated immune responses. Voclosporin, the active ingredient in LUPKYNIS, is made by a modification of a single amino acid of the cyclosporine molecule. It also focuses on treatment of autoimmune, fibrotic, and kidney-related diseases. Its product pipeline includes AUR200, AUR300.

Contact details

1203-4464 Markham St
V8Z 7X8
+1 (250) 7084272

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$2.56 billion
Shares in issue:
129.67 million
US dollar

Key personnel

  • George Milne
    Independent Chairman of the Board
  • Peter Greenleaf
    President, Chief Executive Officer, Director
  • Joe Miller
    Chief Financial Officer
  • Stephen Robertson
    Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
  • Matthew Donley
    Executive Vice President, Operations and Strategy
  • Robert Huizinga
    Executive Vice President - Research
  • Glenn Schulman
    Senior Vice President - Corporate Communications and Investor Relations
  • Neil Solomons
    Chief Medical Officer
  • Massimiliano Colao
    Chief Commercial Officer
  • Michael Martin
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.